Zacks Research Brokers Boost Earnings Estimates for Bruker

Bruker Co. (NASDAQ:BRKR) – Equities research analysts at Zacks Research raised their FY2027 earnings estimates for shares of Bruker in a note issued to investors on Tuesday, March 11th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $3.61 per share for the year, up from their previous forecast of $3.60. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share.

Other research analysts have also recently issued research reports about the stock. Barclays decreased their price objective on shares of Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a report on Monday, February 10th. Bank of America boosted their price objective on shares of Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a report on Friday, December 13th. UBS Group began coverage on shares of Bruker in a report on Tuesday, December 10th. They set a “neutral” rating and a $66.00 price objective for the company. Stifel Nicolaus decreased their price objective on shares of Bruker from $70.00 to $57.00 and set a “hold” rating for the company in a report on Friday, February 14th. Finally, The Goldman Sachs Group upgraded shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective for the company in a report on Thursday, December 5th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $70.50.

Bruker Stock Up 2.2 %

Shares of NASDAQ:BRKR opened at $45.97 on Thursday. Bruker has a one year low of $44.11 and a one year high of $94.86. The company has a 50 day moving average of $53.93 and a 200-day moving average of $58.57. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77. The stock has a market cap of $6.97 billion, a price-to-earnings ratio of 60.49, a P/E/G ratio of 2.16 and a beta of 1.18.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date is Monday, March 17th. Bruker’s dividend payout ratio (DPR) is currently 26.32%.

Institutional Investors Weigh In On Bruker

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FMR LLC increased its position in shares of Bruker by 21.4% in the third quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock valued at $987,981,000 after acquiring an additional 2,521,904 shares during the last quarter. London Co. of Virginia grew its stake in Bruker by 78.4% in the fourth quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company’s stock valued at $245,820,000 after purchasing an additional 1,843,294 shares in the last quarter. State Street Corp increased its position in shares of Bruker by 9.6% during the 3rd quarter. State Street Corp now owns 3,627,300 shares of the medical research company’s stock worth $250,501,000 after purchasing an additional 318,808 shares during the last quarter. RTW Investments LP raised its stake in shares of Bruker by 1.1% during the 3rd quarter. RTW Investments LP now owns 3,481,119 shares of the medical research company’s stock worth $240,406,000 after purchasing an additional 37,024 shares in the last quarter. Finally, Brown Advisory Inc. boosted its holdings in shares of Bruker by 10.1% in the 4th quarter. Brown Advisory Inc. now owns 2,026,712 shares of the medical research company’s stock valued at $118,806,000 after buying an additional 185,912 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.